Eficacia y seguridad de fármacos biosimilares de Etanercept e Infliximab para el tratamiento de Artritis Reumatoide

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease. There are 44.6 cases per 100,000 inhabitants, impairing patients' quality of life by affecting the joints' functionality. Various treatments are available, including biologics such as tumor necrosis factor inhibitors, which include Etanercept and Infliximab. The rise of biosimilar drugs represents improved possibilities for drug access, including the promise of lower costs. Demonstrating the efficacy and safety of biosimilar drugs could redirect their acquisition since, in controlled trials, the only adverse event that occurred more frequently in patients treated with Etanercept and Infliximab were mild to moderate injection site reactions. Therefore, no significant changes were identified during treatment compared to their original biologics. Although Infliximab biosimilars are generally well tolerated, late infusion reactions, which occur 24 hours to 14 days after an infusion and are usually characterized by myalgia, arthralgia, fever, urticaria, and malaise, are noteworthy. It is an essential reason for discontinuing treatment in some patients. However, studies suggest that Etanercept and Infliximab biosimilars benefit patients with RA. Regarding their safety, the rates of adverse events, treatment discontinuation, and immunogenicity responses are similar to those of their reference biologics.